Following the injection of hepatobiliary contrast agents, MRI detects all molecules included in a region of interest but cannot estimate true concentrations in sinusoids, interstitium, hepatocytes or bile canaliculi. The aim of the study was to measure true concentrations in hepatocytes and to show how transfer rates across sinusoidal and canalicular membranes generate these concentrations. We perfused livers isolated from normal rats with 200 μM Gd-DTPA and Gd-BOPTA and measured clearances from sinusoids to liver and from hepatocytes to bile canaliculi or back to interstitium. We detected Gd-BOPTA with a gamma probe and determined true concentrations in each liver compartment knowing their liver volumes. No pharmacokinetic modelling was applied. Gd-BOPTA clearance from sinusoids to liver (2.5 ± 0.4 mL/min) was 50 times higher than that of Gd-DTPA (0.05 ± 0.02 mL/min) when portal flow rate was 30 mL/min (p < 0.0001). Gd-BOPTA clearance from sinusoids to liver was always superior to hepatocyte clearance, and hepatocyte Gd-BOPTA concentrations measured by the probe increased over time. Gd-BOPTA concentrations reached 439 ± 83 μM in hepatocytes and 15 × 700 ± 3100 μM in bile canaliculi, while concentrations in sinusoids were 200 μM. Gd-BOPTA true concentrations in hepatocytes depend on the simultaneous clearances from sinusoids to hepatocytes and from hepatocytes to bile canaliculi and back to sinusoids. The study better defines how signal intensities are generated when hepatobiliary contrast agents are injected in clinical imaging.
INTRODUCTION
Over the past years, several publications have investigated the transporter-mediated hepatic pharmacokinetics of hepatobiliary contrast agents to detect and characterize focal lesions and to score liver function in chronic diseases (1) (2) (3) . For liver magnetic resonance imaging (MRI), two hepatobiliary contrast agents (Gd-BOPTA, MultiHance®, Bracco Imaging, Milan, Italy, and Gd-EOB-DTPA, Primovist®, Bayer Pharma, Berlin, Germany) are available (4) . In the liver, these agents distribute into sinusoids and interstitium before entering hepatocytes across organic anion transporting polypeptides (OATPs), to reach across the canalicular transporter multiple resistance-associated protein 2 (Mrp2) bile canaliculi ( Fig. 1 ) (5) (6) (7) (8) . When transported inside hepatocytes, Gd-EOB-DTPA may return to sinusoids across the sinusoidal MRP3 transporters (9) . Efflux transporters of Gd-BOPTA back to sinusoids are unknown.
The most useful pharmacokinetic parameters to obtain following the injection of hepatobiliary contrast agents are true concentrations generated in each liver compartment according to transfer rates between two adjacent compartments. Liver tissue is divided in sinusoids, interstitium, hepatocytes and bile canaliculi. In clinical MRI, concentrations from each compartment cannot be estimated and there are averaged by a single signal intensity measured in the entire region of interest (ROI). Transfer rates between two liver compartments are not measured but are estimated by pharmacokinetic modelling (10) (11) (12) (13) (14) (15) . However, it is important to measure true concentrations inside each compartment, because concentrations across membranes partly regulate transfer rates across them (16) . In liver tissue, signal intensities given by MR systems do not estimate true concentrations. In the common bile duct, signal intensities estimate true concentrations because the structure has a single compartment. In portal and hepatic veins, signal intensities estimate true concentrations once the volume of blood cells has been subtracted. The aim of the study was to measure true concentrations in hepatocytes and show how transfer rates across sinusoidal and canalicular membranes generate these concentrations. No pharmacokinetic modelling was applied.
METHODS

Experimental groups
In a previous study (17) , we published how Gd-BOPTA accumulates in rat livers in two experimental groups: normal SpragueDawley rats (B200, n = 5) and rats lacking Mrp2 (B200TR, n = 3). We returned to raw data of these two groups to analyse and calculate all parameters available in the present manuscript (Fig. 1A) . Thus, no additional rats were used in the present study.
Isolated and perfused rat livers
Rat livers were isolated and perfused with the experimental protocol previously published (17, 18) . Briefly, two catheters were introduced into portal vein and right atrium. The hepatic artery was not perfused. The system included a reservoir, pump, heating circulator, bubble trap, filter and oxygenator. Livers were perfused with a Krebs-Henseleit bicarbonate (KHB) solution ± contrast agents using a non-recirculating system, livers being always perfused by fresh solutions. The portal flow rate was 30 mL/min. The common bile duct was cannulated to measure Gd-BOPTA bile concentrations (μM) every 5 min and bile flow rates (μL/min). Samples were collected from hepatic veins every 5 min to measure Gd-BOPTA hepatic vein concentrations (μM). Livers were perfused with a constant portal flow rate (30 mL/min). We distinguish a drug perfusion period when Gd-BOPTA accumulates in all liver compartments and a rinse period during which Gd-BOPTA leaves hepatocytes for bile canaliculi or sinusoids. To ensure that Gd-BOPTA measured in hepatic veins originates from hepatocytes, parameters of efflux back to sinusoids are calculated from 85 to 105 min after a 10 min rinse period (corresponding to a 300 mL rinse volume, dashed grey line).
2.3. Drug preparation and protocol of perfused solutions (Fig. 1B) Gadopentetate dimeglumine (Gd-DTPA, Magnevist®, Bayer Pharma) and gadobenate dimeglumine (Gd-BOPTA, MultiHance®, Bracco Imaging) were successively perfused. Contrast agents were labelled by adding 153 GdCl 3 to a 0.5 M Gd-BOPTA or Gd-DTPA solution (1 MBq/mL). Contrast agents were diluted in KHB solution to obtain a 200 μM concentration. Livers were successively perfused with 200 μM DTPA for 10 min, KHB solution for 35 min, 200 μM Gd-BOPTA (perfusion period, 30 min) and KHB solution (rinse period, 30 min). We distinguish a drug perfusion period when Gd-BOPTA accumulates in all liver compartments, and a rinse period during which Gd-BOPTA leaves hepatocytes into bile canaliculi or back to sinusoids.
Liver Gd-DTPA and Gd-BOPTA concentrations
To quantify liver concentrations, a gamma scintillation probe that measures radioactivity every 20 s was placed 1 cm above a liver segment. To transform radioactivity count rates into concentrations, the Gd-BOPTA concentration in each liver (end of experiment) was measured by an activimeter (Isomed 2000, Canberra, Saint-Quentin-en-Yvelines, France) and related to the last count rate measured by the probe. Gd-DTPA and Gd-BOPTA concentrations in the common bile duct and hepatic veins were measured every 5 min with a gamma counter (Canberra). Concentrations are expressed as μM in great vessels, bile duct and livers. In the liver, we consider 1 g to be close to 1 mL.
Gd-BOPTA concentrations in bile canaliculi and hepatocytes (Fig. 1)
Probe bile canaliculus concentrations were calculated by multiplying bile concentrations measured in common bile duct by 0.43%, the volume of bile canaliculi in liver tissue according to Blouin et al. (19) . Throughout the manuscript, concentrations measured by the probe are designated 'probe concentrations' while concentrations inside each compartment are named 'true concentrations'. Knowing Gd-BOPTA probe concentrations in bile canaliculi and the extracellular compartment (given by Gd-DTPA liver probe), we subtracted both values from Gd-BOPTA total liver probe concentrations to obtain Gd-BOPTA probe concentrations in hepatocytes. Finally, because the probe counts Gd-BOPTA in a 78% volume of hepatocytes (19), we must increase the values to 100% to obtain true hepatocyte concentrations.
Transfer rates across membranes (Fig. 1)
Elimination from sinusoids to liver ( SIN ELIMR LIVER ) was measured by (C PV À C HV ) × 30 (constant portal blood flow, mL/min), and sinusoidal clearance to liver ( SIN CL LIVER ) was SIN ELIMR LIVER /C PV , where C PV is the Gd-BOPTA concentration in the portal vein and C HV is the Gd-BOPTA concentration in the hepatic vein. We measured the Gd-BOPTA sinusoidal extraction ratio to liver ( SIN ER LIVER ) as 100 × [C PV À C HV ]/C PV . Gd-DTPA SIN ELIMR LIVER , SIN CL LIVER and SIN ER LIVER were also calculated.
To quantify Gd-BOPTA uptake rate from interstitium into hepatocytes or INT UPTR HC (μM/min), we measured the slope of the relation between true Gd-BOPTA concentrations in hepatocytes and time (min). The parameter was measured over 2 min at the very beginning of the perfusion period, after a delay of 1 min to assure Gd-BOPTA distribution within the extracellular space. This short period of measurement precludes underestimation of hepatocyte concentrations associated with early Gd-BOPTA bile excretion. A single value is available. SIN UPTR LIVER in μM/min was also measured, because it corresponds to liver enhancement measured in clinical imaging.
Transfer rates from hepatocytes to bile canaliculi or interstitium were also measured. HC ELIMR BC (nmol/min) was C BC × bile flow, where C BC is Gd-BOPTA concentration in bile canaliculi.
HC ELIMR INT (nmol/min) was C HV × portal flow rate, where C HV is Gd-BOPTA concentration in the hepatic vein. HC CL BC ( HC ELIMR BC /C HC) and HC CL INT ( HC ELIMR INT /C HC ) were also caculated, where C HC is Gd-BOPTA concentration in hepatocytes.
Statistics
Parameters are means ± SD. To compare the evolution of concentrations over time, we use two-way ANOVA with multiple comparisons between groups within each time-point (Prism 6, GraphPad, La Jolla, CA, USA). Kruskal-Wallis tests compared mean values between the two experimental groups.
RESULTS
Pharmacokinetic parameters of Gd-DTPA
In both groups, liver Gd-DTPA probe concentrations reached steady concentrations (62 ± 10 μM) within 2 min (p = 0.9; Fig. 2 and Table 1 ). The true concentrations in sinusoids are around 200 μM, while the probe measures 20 μM (200 × 0.10) in sinusoids, sinusoidal volume being 10% of tissue volume (19) . Consequently, the probe would measure in interstitium 42 μM (liver -sinusoid probe concentrations). Two different concentrations in sinusoids and interstitium does not fit with the common knowledge of a single concentration in the extracellular volume. Whether the extracellular volume has one or two concentrations is impossible to define with our experimental model. However, an important finding is that concentrations measured by the probe are not the true compartmental concentrations. This point Figure 2 . Gd-DTPA liver probe concentrations measured using the gamma probe placed over the livers for 25 min. Two groups were studied: normal rats (B200, black symbols, n = 5) and rats lacking Mrp2 (B200TR, grey symbols, n = 3). Livers were perfused with 200 μM DTPA (0 to 10 min) and KHB (10 to 25 min, horizontal bar). Concentrations are similar over time in the two groups (p = 0.9). Extracellular space is mostly cleared of DTPA after 2 min. is important to mention because transfer rates between two adjacent compartments rely on true concentrations.
DTPA SIN ELIMR LIVER , SIN CL LIVER and SIN ER LIVER were 9±5 nmol/min, 0.05 ± 0.02 mL/min and 0.15 ± 0.08% respectively in the B200 group and 9 ± 6 nmol/min, 0.04 ± 0.04 mL/min and 0.15 ± 0.13% in the B200TR group (Table 2) . During the rinse period, the extracellular space was mostly cleared of contrast agent within 2 min (Fig. 2) .
Gd-BOPTA concentrations in liver, common bile duct and great vessels
We first illustrate Gd-BOPTA probe concentrations in compartments that are available in clinical liver MRI (Fig. 3) . In the B200 group, liver probe concentrations were much higher (maximal concentrations 473 ± 56 μM, Fig. 3A and Table 1 ) than those measured during Gd-DTPA perfusion. Gd-BOPTA concentrations increase rapidly over 10 min. Thereafter, increase of liver Gd-BOPTA concentrations was slower. When Gd-BOPTA perfusion was replaced by a KHB perfusion (rinse period), Gd-BOPTA liver concentrations steadily decreased (Fig. 3A and Table 1 ).
Gd-BOPTA in common bile duct ( Fig. 3B and Table 1 ) was present 5 min after the start of drug perfusion (first sampling), and maximal true concentrations reached 15 700 ± 3100 μM (end of perfusion period), a concentration 78 times higher than that perfused in portal veins (200 μM). True Gd-BOPTA concentrations in hepatic veins remained around 186 ± 1 μM at steady state ( Fig. 3C and Table 1 ).
In rats lacking Mrp2, liver probe concentrations linearly increased during the perfusion period (Fig. 3A) , Gd-BOPTA accumulating in the absence of transfer into bile canaliculi.
Concentrations were much higher in livers lacking Mrp2 than in normal livers (Fig. 3A and Table 1 ), while Gd-BOPTA true concentrations in common duct were tiny ( Fig. 3B and Table 1 ). When Gd-BOPTA perfusion was replaced by a KHB solution, an early and small decrease in liver concentrations was observed, corresponding to the rinse of extracellular space. Then, Gd-BOPTA remained trapped inside hepatocytes until the end of the protocol.
Gd-BOPTA transfer rates between two compartments
From sinusoids to liver, values differed in the two groups for SIN ELIMR LIVER (p = 0.03), SIN CL LIVER (p = 0.03) and SIN ER LIVER (p = 0.02), values being slightly higher in B200 than B200TR groups ( Table 2 ). The three parameters were high 5 min after the start of Gd-BOPTA perfusion and then decreased to a steady state. At steady state, the Gd-BOPTA liver extraction ratio was 7 ± 1 %, explaining why Gd-BOPTA hepatic vein true concentrations remained high and close to that of the portal vein (Fig. 3C) .
From the relationship between Gd-BOPTA hepatocyte true concentrations and time (Fig. 4A) , we can measure INT UPTR HC at the very beginning of Gd-BOPTA perfusion when HC ELIMR BC and HC ELIMR INT are a minimum. INT UPTR HC were 44 ± 3 (B200 group) and 37 ± 2 μM/min (B200TR group) (p = 0.14). INT UPTCL HC could not be calculated because we do not know the true Gd-BOPTA interstitial concentrations. INT UPTR LIVER values (Gd-BOPTA uptake measured from the relationship between liver probe concentrations and time, similar to liver enhancement in clinical MRI) were 43 ± 5 (B200 group) and 36 ± 4 (B200TR group) (p = 0.10). Thus, signal intensity enhancement at the very Table 2 ).
HC ELIMR BC and HC CL BC values were significantly different between groups (p < 0.0001). HC CL BC in the B200 group was not steady over time (p < 0.006), suggesting that, besides cellular concentrations, other factors determine Gd-BOPTA transfer rates from hepatocytes into bile canaliculi. HC ELIMR INT (p < 0.0001) and HC CL INT (p < 0.0001) over time also significantly differed between groups. At the end of the protocol, we calculated that Gd-BOPTA clearance from hepatocytes back to sinusoids represents 15% of Gd-BOPTA clearance from hepatocytes.
How transfer rates determine hepatocyte Gd-BOPTA true concentrations
Finally, Fig. 4B clearly explains how Gd-BOPTA transfer rates generate Gd-BOPTA concentrations in hepatocytes. At the begining of perfusion, Gd-BOPTA SIN ELIMR LIVER was much higher than Gd-BOPTA HC ELIMR BILE in the B200 group. Then, SIN ELIMR LIVER decreased but remained higher than HC ELIMR BILE and hepatocyte concentrations continued to increase moderately. The absence of Gd-BOPTA HC ELIMR BILE clearly explains the high hepatocyte concentrations in B200TR group.
DISCUSSION
Without any pharmacokinetic modelling, we measure true concentrations in each compartment (except interstitium) and evidence how transfer rates generate concentrations in hepatocytes. Gd-BOPTA true concentrations in hepatocytes depend on simultaneous clearances from sinusoids to hepatocytes and from hepatocytes to bile canaliculi and back to sinusoids. Clearly, biliary clearance of Gd-BOPTA should be kept in mind besides uptake clearance when analysing signal intensities in the hepatobiliary phase of clinical MRI. Various findings important for the understanding of signal intensities obtained in the hepatobiliary phase of human liver imaging are listed in the following paragraphs.
First, we distinguish 'true concentrations' from 'probe concentrations' in all compartments included in the liver. Concentrations calculated from signal intensities with clinical MR systems correspond to our 'probe concentrations' and are not true tissue concentrations. These systems, similarly to our probe, detect all molecules included in the ROI delineated by the system (probe or MRI) without any possibility to localize concentrations in each Another finding is that clearance from sinusoids into liver is 50 times higher during Gd-BOPTA than Gd-DTPA perfusion. At steady state, Gd-BOPTA SIN CL LIVER is 2.5 mL/min when portal flow is 30 mL/min. By definition, it is independent of sinusoidal concentrations, but other factors interfere with the values because SIN CL LIVER is higher 5 min after the start of Gd-BOPTA than at the end of perfusion. Moreover, Gd-BOPTA SIN CL LIVER is inhomogeneous along sinusoids because few OATP transporters are expressed in hepatocytes around portal triads in humans and rodent livers, while the expression progressively increases until Gd-BOPTA reaches perivenous hepatocytes (21) (22) (23) . Consequently, Gd-BOPTA clearance increases along sinusoids (Fig. 6 ). This finding suggests that a decreased enhancement in the hepatobiliary phase would be evidenced mainly when injury occurs in perivenous hepatocytes. This zonal distribution of Gd-BOPTA clearance is impossible to measure with the gamma probe, which targets a large volume of tissue. This zonal distribution can be modelled by several compartments inside livers (24, 25) .
Another observation is the low Gd-BOPTA extraction ratio (7%) in a single pass, which explains the high hepatic vein concentrations. Radioactivity is sensitive enough to detect Gd-BOPTA entry into hepatocytes 33 s after the start of perfusion. In clinical MRI, accumulation in hepatocytes should be high enough to be detected and hepatobiliary sequences are acquired 20 min (Gd- EOB-DTPA) or 120 min (Gd-BOPTA) after injection. However, early hepatocyte uptake has been recently evidenced (26) .
The best interval to measure signal intensity enhancement in human livers remains puzzling. We detected Gd-BOPTA entry into hepatocytes between 1 and 3 min after the start of Gd-BOPTA perfusion. During this interval, Gd-BOPTA had time to distribute into the extracellular volume and few Gd-BOPTA molecules reached bile canaliculi. A similar interval is chosen in SPECT imaging following the injection of 99m Tc-mebrofenin, which is transported by the same transporters as Gd-BOPTA and Gd-EOB-DTPA (27) . We also show that Gd-BOPTA uptake rates from interstitium to hepatocytes ( INT UPTR HC ) or liver ( INT UPTR LIVER ) were similar, suggesting that signal intensity enhancement in clinical MRI correctly estimates Gd-BOPTA uptake rates from interstitium into hepatocytes.
Finally, Gd-BOPTA true concentrations in hepatocytes depend on SIN CL LIVER , HC CL BC and HC CL INT . Gd-BOPTA accumulation in hepatocytes over time is linear when bile clearance is impeded (9, 13) . In contrast, the inflection of hepatocyte concentration curve over time we describe during Gd-BOPTA perfusion corresponds to the concomitant Gd-BOPTA bile excretion, which minimizes concentration increase.
Gd-BOPTA efflux back from hepatocytes into sinusoids is less important because HC CL INT is 15% when HC CL INT is 85%. Thus, signal intensities in clinical imaging estimate hepatocyte concentrations generated by simultaneous Gd-BOPTA hepatocyte uptake and exit rates. This conclusion is proven in hepatocarcinomas that retain OATP1B1/B3 expression on tumour cells. These lesions are either hypointense if Mrp2 expression is increased (increased Gd-EOB-DTPA bile excretion) or hyperintense when Mrp2 expression is decreased (28).
Limitations of the study
Gd-BOPTA perfusion over 30 min in rat perfused liver does not mimic clinical protocols. Moreover, the hepatic artery is not perfused and the dual imput of Gd-BOPTA entry into livers is not respected. Portal flow rate is constant over the protocol, while food intake may increase portal blood flow in humans. The absence of albumin in the perfusion solution provides a maximal Gd-BOPTA entry into hepatocytes, while Gd-BOPTA uptake into human hepatocytes depends on plasma albumin concentrations.
